<DOC>
	<DOC>NCT02520284</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of GS-5745. It will consist of 3 parts: Induction Study (Cohort 1), and Maintenance Study (Cohort 2), and an Extended Treatment Phase.</brief_summary>
	<brief_title>Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Ulcerative Colitis (UC) confirmed on endoscopy Moderately to severely active UC (Mayo Score 612) May be receiving oral 5aminosalicylate (ASA), oral corticosteroid, Azathioprine, 6mercaptopurine(MP), or methotrexate Treatment failure with at least one of the following agents received; Corticosteroids, Immunomodulators, tumor necrosis factoralpha (TNFÎ±) Antagonists, Vedolizumab Key Diagnose of Crohn's disease or indeterminate colitis Pregnant or lactating females Any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse) Exhibit severe UC / clinically significant active infection History of malignancy in the last 5 years Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>